A leading cancer centre has described ANGLE's Parsotix liquid biopsy for the detection of cancer as "demonstrating significant advantages" in detecting circulating tumour cells (CTCs) in the bloodstream versus other technologies, saying its technique delivers isolated CTCs at a very high purity, and captures a broad range of cells, to enable a detailed diagnosis. The study was led by Professor David King from Cancer Research UK who is also director of the Institute of Molecular Medicine (IMM).
A leading cancer centre has described ANGLE's Parsotix liquid biopsy for the detection of cancer as "demonstrating significant advantages" in detecting circulating tumour cells (CTCs) in the bloodstream versus other technologies, saying its technique delivers isolated CTCs at a very high purity, and captures a broad range of cells, to enable a detailed diagnosis. So-called liquid biopsies to diagnose cancer have long been a goal of biotechnology companies, as detecting cancer earlier gives doctors a better chance to treat it.